Agoracom: Small Cap Investment - Zenith Epigenetics - Re: Bear - Zenith valuation today, my guess $500M tops or around $4/share. Who's willing to take $4 now?

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Payzone

Rank: Mail Room [?]

Points: 203 [?]

Votes: 6 Score: 4.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Bear - Zenith valuation today, my guess $500M tops or around $4/share. Who's willing to take $4 now?

in response to

Bear

Telepanel

posted on Oct 09, 2020 04:05PM

Not me. I think we're 2+ years and a successful phase 2(b) cancer trial away from $1Billion+ valuation. I'm being conservative here since Don can't get a decent market valuation for RVX.

12-18 months to results that the market can take seriously and 1 year to either an IPO or an acquisition from a trial partner. I'll guess end of 2022 or first half of 2023 before we can get paid.

Should all 3 of Zenith's Phase 2 trials show positive results then I'll double my valuation guess to $2+ Billion.

I think you need patience and a bit of good luck to see a $Billion valuation in the next 2+ years. If anything, Covid is going to slow these trials down and delay results.